GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (STU:8BT) » Definitions » Shiller PE Ratio
中文

BriaCell Therapeutics (STU:8BT) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2016. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics Shiller PE Ratio Historical Data

The historical data trend for BriaCell Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, BriaCell Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Shiller PE Ratio falls into.



BriaCell Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BriaCell Therapeutics's E10 for the quarter that ended in Jan. 2024 is calculated as:

For example, BriaCell Therapeutics's adjusted earnings per share data for the three months ended in Jan. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.652/125.4675*125.4675
=-0.652

Current CPI (Jan. 2024) = 125.4675.

BriaCell Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -6.444 98.920 -8.173
201407 -92.504 99.315 -116.863
201410 -0.244 99.473 -0.308
201501 -8.117 98.209 -10.370
201504 -2.306 99.710 -2.902
201507 -1.409 100.579 -1.758
201510 -2.045 100.500 -2.553
201601 -1.977 100.184 -2.476
201604 -2.106 101.370 -2.607
201607 -1.826 101.844 -2.250
201610 -2.031 102.002 -2.498
201701 -2.152 102.318 -2.639
201704 -4.103 103.029 -4.997
201707 -8.168 103.029 -9.947
201710 -1.990 103.424 -2.414
201801 -1.994 104.056 -2.404
201804 -1.904 105.320 -2.268
201807 5.972 106.110 7.061
201810 -1.280 105.952 -1.516
201901 -1.941 105.557 -2.307
201904 -1.717 107.453 -2.005
201907 -2.356 108.243 -2.731
201910 -1.655 107.927 -1.924
202001 -1.780 108.085 -2.066
202004 -0.643 107.216 -0.752
202007 -1.160 108.401 -1.343
202010 -0.459 108.638 -0.530
202101 -0.246 109.192 -0.283
202104 0.527 110.851 0.596
202107 -0.892 112.431 -0.995
202110 -1.560 113.695 -1.722
202201 0.628 114.801 0.686
202204 -0.602 118.357 -0.638
202207 -0.029 120.964 -0.030
202210 -0.071 121.517 -0.073
202301 -0.715 121.596 -0.738
202304 -0.292 123.571 -0.296
202307 -0.136 124.914 -0.137
202310 -0.473 125.310 -0.474
202401 -0.652 125.468 -0.652

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics  (STU:8BT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BriaCell Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (STU:8BT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (STU:8BT) Headlines

No Headlines